WallStreetZenWallStreetZen

NASDAQ: RVPH
Reviva Pharmaceuticals Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RVPH

Based on 3 analysts offering 12 month price targets for Reviva Pharmaceuticals Holdings Inc

Min Forecast
$40.00+5,008.56%
Avg Forecast
$53.33+6,711.37%
Max Forecast
$80.00+10,117.11%

Should I buy or sell RVPH stock?

Based on 3 analysts offering ratings for Reviva Pharmaceuticals Holdings Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RVPH's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RVPH as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their RVPH stock forecasts and price targets.

RVPH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-05
lockedlocked$00.00+00.00%2025-12-23
lockedlocked$00.00+00.00%2025-12-23

1 of 1

Forecast return on equity

Is RVPH forecast to generate an efficient return?

Company
89.15%
Industry
69.63%
Market
165.82%
RVPH's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RVPH forecast to generate an efficient return on assets?

Company
48.42%
Industry
31.75%
RVPH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RVPH earnings per share forecast

What is RVPH's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$4.05
Avg 2 year Forecast
-$4.49
Avg 3 year Forecast
-$5.97

RVPH revenue forecast

What is RVPH's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$105.4M

RVPH vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RVPH$0.78$53.33+6,711.37%Strong Buy
CALC$0.64$10.00+1,460.06%Buy
LNAI$0.39N/AN/A
CVKD$4.32$13.00+200.93%Buy
BIVI$1.44N/AN/A
View Top Biotech Stocks

Reviva Pharmaceuticals Holdings Stock Forecast FAQ

Is Reviva Pharmaceuticals Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: RVPH) stock is to Strong Buy RVPH stock.

Out of 3 analysts, 2 (66.67%) are recommending RVPH as a Strong Buy, 1 (33.33%) are recommending RVPH as a Buy, 0 (0%) are recommending RVPH as a Hold, 0 (0%) are recommending RVPH as a Sell, and 0 (0%) are recommending RVPH as a Strong Sell.

If you're new to stock investing, here's how to buy Reviva Pharmaceuticals Holdings stock.

What is RVPH's earnings growth forecast for 2026-2028?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.66%.

Reviva Pharmaceuticals Holdings's earnings in 2026 is -$19,864,902.On average, 9 Wall Street analysts forecast RVPH's earnings for 2026 to be -$51,852,563, with the lowest RVPH earnings forecast at -$90,390,020, and the highest RVPH earnings forecast at -$29,726,480. On average, 7 Wall Street analysts forecast RVPH's earnings for 2027 to be -$57,492,972, with the lowest RVPH earnings forecast at -$100,433,356, and the highest RVPH earnings forecast at -$6,187,412.

In 2028, RVPH is forecast to generate -$76,526,630 in earnings, with the lowest earnings forecast at -$115,498,359 and the highest earnings forecast at -$4,976,831.

What is RVPH's revenue growth forecast for 2026-2028?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.82%.

Reviva Pharmaceuticals Holdings's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast RVPH's revenue for 2026 to be $0, with the lowest RVPH revenue forecast at $0, and the highest RVPH revenue forecast at $0. On average, 6 Wall Street analysts forecast RVPH's revenue for 2027 to be $0, with the lowest RVPH revenue forecast at $0, and the highest RVPH revenue forecast at $0.

In 2028, RVPH is forecast to generate $1,350,085,632 in revenue, with the lowest revenue forecast at $262,382,142 and the highest revenue forecast at $2,498,535,930.

What is RVPH's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RVPH) forecast ROA is 48.42%, which is higher than the forecast US Biotechnology industry average of 31.75%.

What is RVPH's Price Target?

According to 3 Wall Street analysts that have issued a 1 year RVPH price target, the average RVPH price target is $53.33, with the highest RVPH stock price forecast at $80.00 and the lowest RVPH stock price forecast at $40.00.

On average, Wall Street analysts predict that Reviva Pharmaceuticals Holdings's share price could reach $53.33 by Jan 5, 2027. The average Reviva Pharmaceuticals Holdings stock price prediction forecasts a potential upside of 6,711.37% from the current RVPH share price of $0.78.

What is RVPH's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's current Earnings Per Share (EPS) is -$5.48. On average, analysts forecast that RVPH's EPS will be -$4.05 for 2026, with the lowest EPS forecast at -$7.06, and the highest EPS forecast at -$2.32. On average, analysts forecast that RVPH's EPS will be -$4.49 for 2027, with the lowest EPS forecast at -$7.84, and the highest EPS forecast at -$0.48. In 2028, RVPH's EPS is forecast to hit -$5.97 (min: -$9.02, max: -$0.39).

What is RVPH's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RVPH) forecast ROE is 89.15%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.